Solid but not spectacular: Victoza's weight loss verdict in non-diabetics
This article was originally published in Scrip
Executive Summary
Despite reporting positive weight loss data from the third of four Phase IIIa trials from the SCALE program investigating liraglutide (Victoza) for obesity Novo Nordisk has failed to dazzle analysts who have questioned the commercial potential of the drug in this arena.